title: Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis.
abstract: OBJECTIVE
  To examine whether poly-unsaturated fatty acid (PUFA) therapy is beneficial for improving nonalcoholic steatohepatitis (NASH).
  
  
  METHODS
  In total, 78 patients pathologically diagnosed with NASH were enrolled and were randomly assigned into the control group and the PUFA therapy group (added 50 mL PUFA with 1:1 ratio of EHA and DHA into daily diet). At the initial analysis and after 6 mo of PUFA therapy, parameters of interest including liver enzymes, lipid profiles, markers of inflammation and oxidation, and histological changes were evaluated and compared between these two groups.
  
  
  RESULTS
  At the initial analysis, in patients with NASH, serum levels of alanine aminotransferase (ALT) and aspartase aminotransferase (AST) were slightly elevated. Triglyceride (TG), total cholesterol (TC) and low-density lipoprotein cholesterol levels, markers of systemic inflammation [C-reactive protein (CRP)] and oxidation [malondialdehyde (MDA)], as well as fibrosis parameters of type IV collagen and pro-collagen type III pro-peptide were also increased beyond the normal range. Six months later, ALT and AST levels were significantly reduced in the PUFA group compared with the control group. In addition, serum levels of TG and TC, CRP and MDA, and type IV collagen and pro-collagen type III pro-peptide were also simultaneously and significantly reduced. Of note, histological evaluation showed that steatosis grade, necro-inflammatory grade, fibrosis stage, and ballooning score were all profoundly improved in comparison to the control group, strongly suggesting that increased PUFA consumption was a potential way to offset NASH progression.
  
  
  CONCLUSIONS
  Increased PUFA consumption is a potential promising approach for NASH prevention and reversal.
authors.affiliation: Yun-Hua Li, Tong-Gang Liu, Li-Guo Zhang, Xian-Xian Liu, Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou 256603, Shandong Province, China.
authors.forename: Yun-Hua
authors.initials: YH
authors.lastname: Li
authors.affiliation: Yun-Hua Li, Tong-Gang Liu, Li-Guo Zhang, Xian-Xian Liu, Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou 256603, Shandong Province, China.
authors.forename: Lu-Hua
authors.initials: LH
authors.lastname: Yang
authors.affiliation: Yun-Hua Li, Tong-Gang Liu, Li-Guo Zhang, Xian-Xian Liu, Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou 256603, Shandong Province, China.
authors.forename: Kai-Hui
authors.initials: KH
authors.lastname: Sha
authors.affiliation: Yun-Hua Li, Tong-Gang Liu, Li-Guo Zhang, Xian-Xian Liu, Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou 256603, Shandong Province, China.
authors.forename: Tong-Gang
authors.initials: TG
authors.lastname: Liu
authors.affiliation: Yun-Hua Li, Tong-Gang Liu, Li-Guo Zhang, Xian-Xian Liu, Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou 256603, Shandong Province, China.
authors.forename: Li-Guo
authors.initials: LG
authors.lastname: Zhang
authors.affiliation: Yun-Hua Li, Tong-Gang Liu, Li-Guo Zhang, Xian-Xian Liu, Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou 256603, Shandong Province, China.
authors.forename: Xian-Xian
authors.initials: XX
authors.lastname: Liu
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D002681:China; D019587:Dietary Supplements; D018450:Disease Progression; D004281:Docosahexaenoic Acids / Q000627:therapeutic use*; D015118:Eicosapentaenoic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid
keywords: Management; Nonalcoholic steatohepatitis; Poly-unsaturated fatty acid